# OnCo record immune-colitis (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/immune-colitis/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "immune-colitis" ;
  schema:name "Immune-mediated colitis and diarrhoea"@en ;
  schema:alternateName "colitis"@en, "immune colitis"@en, "immune-mediated colitis"@en, "checkpoint colitis"@en, "ipilimumab colitis"@en, "diarrhoea"@en, "diarrhea"@en, "grade 3 diarrhoea"@en, "severe diarrhoea"@en, "enterocolitis"@en ;
  schema:description "Inflammation of the bowel caused by immunotherapy releasing the immune system against the gut lining, producing diarrhoea that can be severe. It is the commonest serious side effect of CTLA-4 antibodies and is treated with steroids and, if needed, infliximab."@en ;
  schema:url <https://onco.cc/terms/immune-colitis/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Colitis> ;
  schema:citation <https://en.wikipedia.org/wiki/Colitis>, <https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/pembrolizumab>, <https://doi.org/10.1200/JCO.21.01440>, <https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/pembrolizumab> ;
  onco:related <https://onco.cc/terms/irae/>, <https://onco.cc/terms/immune-endocrinopathy/>, <https://onco.cc/terms/dose-modification/> ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/lung-cancer/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/> ;
  onco:sections <https://onco.cc/fronts/supportive-care/>, <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/microbiome-modulation-io/> ;
  onco:drugs <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/irinotecan/> .